Kymera Therapeutics Inc. reported first‑quarter 2026 financial results, posting revenue of $34.4 million and a net loss of $69.2 million. Cash and cash equivalents stood at $1.55 billion as of March 31, 2026, giving the company a runway that extends into 2029.
Revenue surged 329% versus the consensus estimate of $8.01 million, driven almost entirely by a $34.4 million collaboration revenue from its partnership with Gilead Sciences. The collaboration revenue grew 55% year‑over‑year from $22.1 million in Q1 2025. The company also highlighted the potential for nearly $1 billion in milestone payments from its Sanofi partnership, with KT‑485 expected to enter Phase 1 this year.
Net loss widened to $69.2 million from $65.6 million in Q1 2025, but the earnings per share of –$0.71 beat the consensus estimate of –$0.88, a 19% improvement. The narrower loss reflects disciplined cost management amid continued investment in research and development.
Research and development expenses rose to $98.2 million, up from $88.5 million in the prior quarter, as the company expanded its STAT6 and IRF5 programs and accelerated the development of its platform and discovery assets. General and administrative expenses increased due to legal and professional services, personnel, and facility costs, but the company expects G&A growth to moderate in coming quarters.
Kymera’s pipeline remains a key driver of its outlook. Phase IIb trials for KT‑621 and Phase I trials for KT‑579 continue, while the Gilead‑partnered KT‑200 program is moving toward an IND filing in 2027. The company recognized a $40 million upfront payment from Gilead in Q1 2026 and expects a $45 million investment in Q2 2026, with additional milestone payments potentially reaching $700 million.
Investors reacted positively to the results, citing the strong revenue beat, EPS beat, and FDA Fast Track designation for KT‑621 in asthma and atopic dermatitis. Management emphasized disciplined execution and the continued progress of its degrader technology, stating, 'As we continue to advance KT‑621 and KT‑579 through clinical development, our focus remains on disciplined execution and delivering on multiple important milestones this year.'
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.